Iter-4360dd15-0093-transcript
第 93 轮执行轨迹
→ call search_memory({"limit":10,"query":"4360dd15 38310895 原始人类试验 PMID 主要终点"}) → call list_recent({"n":8})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0090-transcript", "tags": "iteration transcript", "modified": "20260424210019000", "preview": "!! 第 90 轮执行轨迹 → call search_memory({\\\"limit"}, {"title": "Iter-4360dd15-0051-transcript", "tags": "iteration transcript", "modified": "20260424194527000", "preview": "!! 第 51 轮执行轨迹 【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0092-reflection", "modified": "20260424210407000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424210407000", "tags": "pinned focus"}, {"title": "先锁定唯一 PMID 再判终点", "modified": "20260424210407000", "tags": "lesson evidence-chain clinical-trials endpoint-classification"}, {"title": "Iter-4360dd15-0092-transcript", "modified": "20260424210400000", "tags": "iteration transcript"}, {"title": "PMID 24691032 is muscle-protein-synthesis endpoint, not longevity evidence", "modified": "20260424210355000", "tags": "4360dd15 fact knowledge clinical-trials endpoint-classification"}, {"title": "Iter-4360dd15-0091-reflection", "modified": "20260424210210000", "tags": "iteration reflection"}, {"title": "先锁定唯一引用再看终点", "modified": "20260424210210000", "tags": "lesson evidence-chain clinical-trials endpoint-classification"}, {"title": "Iter-4360dd15-0091-transcript", "modified": "20260424210157000", "tags": "iteration transcript"}]}
→ call search_memory({"limit":10,"query":"4360dd15 38310895"})
→ call read_note({"title":"NEXT_FOCUS"})
→ call list_by_tag({"limit":20,"tag":"4360dd15"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→ call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\"}) → call list_recent({\"n\":10}) → call list_tools({}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0059-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424195947000\", \"preview\": \"!! 第 59 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 PMID 38310895 reference chain Crossref 75 references human trial rapamycin everolimus sirolimus\"}) → call list_recent({\"n\":8}) → call list_tools({}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0010-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424175830000\", \"preview\": \"!! 第 10"}, {"title": "Iter-4360dd15-0090-transcript", "tags": "iteration transcript", "modified": "20260424210019000", "preview": "!! 第 90 轮执行轨迹 【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission 4360dd15 · Iter-0092）\n\n从 38310895 的可访问引用链中找出 1 个尚未审计的原始人类试验 PMID，并只核实它的主要终点。"}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "PMID 24691032 is muscle-protein-synthesis endpoint, not longevity evidence", "modified": "20260424210355000"}, {"title": "PMID 22115710 is phase I ocular safety study, not longevity evidence", "modified": "20260424210145000"}, {"title": "PMID 29408453 is feasibility/safety pilot, not direct longevity evidence", "modified": "20260424210012000"}, {"title": "PMID 31761958 is skin-senescence endpoint, not longevity evidence", "modified": "20260424205759000"}, {"title": "PMID 33977284 is RTI incidence endpoint, not direct longevity evidence", "modified": "20260424204839000"}, {"title": "PMID 25540326 is immune-response endpoint, not longevity evidence", "modified": "20260424204718000"}, {"title": "PMID 27883166 is a pilot safety feasibility trial not direct longevity evidence", "modified": "20260424204543000"}, {"title": "PEARL trial is not direct longevity evidence", "modified": "20260424203525000"}, {"title": "Iter-4360dd15-0078-two-pmid-evidence-verification", "modified": "20260424203242000"}, {"title": "Iter-4360dd15-0077-unified-longevity-classification-four-pmids", "modified": "20260424203137000"}, {"title": "Iter-4360dd15-0075-abstract-field-extraction-two-pmids", "modified": "20260424202951000"}, {"title": "Iter-4360dd15-0072-review-exclusion-first-rule", "modified": "20260424202103000"}, {"title": "Iter-4360dd15-0071-minimal-audit-rules", "modified": "20260424201843000"}, {"title": "Iter-4360dd15-0069-standardized-audit-table-two-trials",
→ call web_search({"limit":8,"query":"38310895 rapamycin review references human trial PMID sirolimus everolimus"})
→ call pubmed_search({"limit":5,"query":"38310895 rapamycin review human trial reference PMID"})
【tool:web_search】
{"ok": true, "query": "38310895 rapamycin review references human trial PMID sirolimus everolimus", "results": [{"title": "Influence of rapamycin on safety and healthspan metrics after one year ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12074816/", "snippet": "An important gap in the clinical understanding of rapamycin for longevity is that to date, no long-term randomized controlled trials (RCT) have been conducted to explore the safety and effectiveness of low-dose, intermittent rapamycin regimens for improving multiple healthspan metrics in normative aging cohorts."}, {"title": "What is the clinical evidence to support off-label rapamycin therapy in ...", "url": "https://www.aging-us.com/article/206300/pdf", "snippet": "ABSTRACT Low dose rapamycin therapy has been proposed as a longevity candidate in healthy aging adults. We present a review of the evidence for low dose rapamycin and rapalog therapies in healthy human adults and model the findings of one cohort study using the PhenoAge model. Despite the preclinical evidence supporting the use of sirolimus to enhance mean and maximal lifespan, the data in ..."}, {"title": "The bioavailability and blood levels of low-dose rapamycin for ...", "url": "https://link.springer.com/article/10.1007/s11357-025-01532-w", "snippet": "Study design This study collected real-world data to better understand the bioavailability of compounded and commercial rapamycin , with a specific focus on observing patterns of rapamycin lev
【tool:pubmed_search】
{"ok": true, "query": "38310895 rapamycin review human trial reference PMID", "results": []}
→ call web_search({"limit":5,"query":"PMID 38310895 rapamycin systematic review human humans references"})
→ call web_search({"limit":5,"query":"\"38310895\" rapamycin systematic review"})
→ call wiki_search({"lang":"en","limit":5,"query":"38310895 rapamycin"})
【tool:web_search】
{"ok": true, "query": "PMID 38310895 rapamycin systematic review human humans references", "results": [{"title": "Targeting ageing with rapamycin and its derivatives in humans: a ...", "url": "https://europepmc.org/article/MED/38310895", "snippet": "Rapamycin and its derivatives improved physiological parameters associated with ageing in the immune, cardiovascular, and integumentary systems of healthy individuals or individuals with ageing-related diseases."}, {"title": "Targeting ageing with rapamycin and its derivatives in humans: a ...", "url": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00258-1/fulltext", "snippet": "The articles were organised and managed using Covidence systematic review software (Veritas Health Innovation, Melbourne, VIC, Australia). To establish the progress of rapamycin and its derivatives in ongoing human studies, we searched ClinicalTrials.gov for relevant trials from database inception to July 2, 2023."}, {"title": "PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/", "snippet": "PubMed® comprises more than 40 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text content from PubMed Central and publisher web sites."}, {"title": "Targeting ageing with rapamycin and its derivatives in humans: a ...", "url": "https://nutrition-evidence.com/article/501551/targeting-ageing-with-rapamycin-and-its-derivatives-in-humans-a-systematic-review", "snippe
【tool:web_search】
{"ok": true, "query": "\"38310895\" rapamycin systematic review", "results": [{"title": "Systemic review study of Rapamycin : r/Rapamycin - Reddit", "url": "https://www.reddit.com/r/Rapamycin/comments/1bo5ogp/systemic_review_study_of_rapamycin/", "snippet": "Last month Ajla Hodzic Kuerec, Deborah Lee and Andrea Maier published a very interesting systematic review of Rapamycin and rapalogs (pubmed: 38310895 ). A systematic review is a review that gathers together different research studies within an area and based on that analyzes and summarizes these."}, {"title": "A systematic review study of Rapamycin", "url": "https://rapamycinlongevitylab.substack.com/p/a-systematic-review-study-of-rapamycin", "snippet": "Last month Ajla Hodzic Kuerec, Deborah Lee and Andrea Maier published a very interesting systematic review of Rapamycin and rapalogs (pubmed: 38310895 )."}, {"title": "Contacts, Subscriber Numbers, Similar Newsletters - Rapamycin Longevity ...", "url": "https://reletter.com/publications/rapamycin-longevity-labs-substack", "snippet": "A systematic review study of Rapamycin Last month Ajla Hodzic Kuerec, Deborah Lee and Andrea Maier published a very interesting systematic review of Rapamycin and rapalogs (pubmed: 38310895 )."}, {"title": "#rapamycin #longevityscience #healthspan #metabolichealth # ...", "url": "https://www.linkedin.com/posts/ranulf-crooke_rapamycin-longevityscience-healthspan-activity-7411401877105491968-uGEr", "snippet": "In humans, a 2024 Lancet Healthy
【tool:wiki_search】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://en.wikipedia.org/w/api.php?action=query&list=search&srsearch=38310895+rapamycin&srlimit=5&format=json'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call web_fetch({"max_chars":12000,"url":"https://europepmc.org/article/MED/38310895"})
→ call web_fetch({"max_chars":12000,"url":"https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00258-1/fulltext"})
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/38310895", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00258-1/fulltext'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call search_memory({"limit":20,"query":"4360dd15 unreviewed original human trial PMID rapamycin review 38310895"})
→ call search_memory({"limit":20,"query":"4360dd15 38310895 included studies PMID trial title"})
→ call search_memory({"limit":20,"query":"4360dd15 PEARL RAPA-EX-01 PMID"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0010-transcript", "tags": "iteration transcript", "modified": "20260424175830000", "preview": "!! 第 10 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 rapamycin review 2024 trial endpoint remaining 11\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0007-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424174944000\", \"preview\": \"!! 第 7 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 rapamycin 2024 systematic review 19 studies Table 1 included trials endpoint\"}) → call list_recent({\"n\":6}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0010-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424175830000\", \"preview\": \"!! 第 10 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 38310895 引用链 原始人类试验 PMID 主要终点\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":8,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"resu【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0090-transcript", "tags": "iteration transcript", "modified": "20260424210019000", "preview": "!! 第 90 轮执行轨迹 → call search_memory({\\\"limit"}, {"title": "Iter-4360dd15-0083-transcript", "tags": "iteration transcript", "modified": "20260424204550000", "preview": "!! 第 83 轮执行轨迹 【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→ call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\"}) → call list_recent({\"n\":10}) → call list_tools({}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0059-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424195947000\", \"preview\": \"!! 第 59 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 38310895 原始人类试验 PMID 主要终点\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":8,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0060-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424200117000\", \"preview\": \"!! 第 60 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd → call web_search({"limit":10,"query":"\"Targeting ageing with rapamycin and its derivatives in humans\" supplementary appendix pdf"})
→ call web_search({"limit":10,"query":"\"Targeting ageing with rapamycin and its derivatives in humans\" pmc full text"})
【tool:web_search】
{"ok": true, "query": "\"Targeting ageing with rapamycin and its derivatives in humans\" supplementary appendix pdf", "results": [{"title": "PDF Supplementary appendix - The Lancet", "url": "https://www.thelancet.com/cms/10.1016/S2666-7568(23)00258-1/attachment/6dc4a44a-1910-4435-ab52-a506c5f070b4/mmc1.pdf", "snippet": "Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Lee DJW, Hodzic Kuerec A, Maier AB. Targeting ageing with rapamycin and its derivatives in humans : a systematic review. Lancet Healthy Longev 2024; 5: e152-62. Table of Contents"}, {"title": "Targeting ageing with rapamycin and its derivatives in humans: a ...", "url": "https://www.sciencedirect.com/science/article/pii/S2666756823002581", "snippet": "Rapamycin and its derivatives (rapalogs) are inhibitors of mTOR, a major regulator of the ageing process. We aimed to summarise the effects of rapamycin and its derivatives on the severity of ageing-related physiological changes and disease in adults. A search across five databases yielded 18 400 unique articles, resulting in 19 included studies. Rapamycin and its derivatives improved ..."}, {"title": "Targeting ageing with rapamycin and its derivatives in humans: a ...", "url": "https://www.researchgate.net/publication/377976071_Targeting_ageing_with_rapamycin_and_its_derivatives_in_humans_a_systematic_review", "snippet": "Request PDF | On Feb 1, 2024, Debo
【tool:web_search】
{"ok": true, "query": "\"Targeting ageing with rapamycin and its derivatives in humans\" pmc full text", "results": [{"title": "Targeting ageing with rapamycin and its derivatives in humans: a ...", "url": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00258-1/fulltext", "snippet": "Rapamycin and its derivatives (rapalogs) are inhibitors of mTOR, a major regulator of the ageing process. We aimed to summarise the effects of rapamycin and its derivatives on the severity of ageing-related physiological changes and disease in adults. A search across five databases yielded 18 400 unique articles, resulting in 19 included studies. Rapamycin and its derivatives improved ..."}, {"title": "Targeting ageing with rapamycin and its derivatives in humans: a ...", "url": "https://europepmc.org/article/MED/38310895", "snippet": "Rapamycin and its derivatives (rapalogs) are inhibitors of mTOR, a major regulator of the ageing process. We aimed to summarise the effects of rapamycin and its derivatives on the severity of ageing-related physiological changes and disease in adults. A search across five databases yielded 18 400 ..."}, {"title": "Targeting ageing with rapamycin and its derivatives in humans: a ...", "url": "https://www.sciencedirect.com/science/article/pii/S2666756823002581", "snippet": "Rapamycin and its derivatives (rapalogs) are inhibitors of mTOR, a major regulator of the ageing process. We aimed to summarise the effects of rapamycin and its derivatives on t
→ call web_fetch({"max_chars":20000,"url":"https://www.thelancet.com/pdfs/journals/lanhl/PIIS2666-7568(23)00258-1.pdf"})
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://www.thelancet.com/pdfs/journals/lanhl/PIIS2666-7568(23)00258-1.pdf'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call web_search({"limit":10,"query":"\"Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01\" PMID"})
→ call web_search({"limit":10,"query":"\"RAPA-EX-01\" rapamycin older adults PMID primary endpoint"})
→ call pubmed_search({"limit":10,"query":"RAPA-EX-01 rapamycin older adults exercise sirolimus"})
【tool:web_search】
{"ok": true, "query": "\"Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01\" PMID", "results": [{"title": "Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 ...", "url": "https://onlinelibrary.wiley.com/doi/10.1002/jcsm.70274", "snippet": "Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 Randomised, Double-Blind, Placebo-Controlled Trial Royal New Zealand College of General Practitioners, Wellington, New Zealand"}, {"title": "Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 ...", "url": "https://society-scwd.org/exercise-and-weekly-sirolimus-rapamycin-in-older-adults-rapa-ex-01-randomised-double-blind-placebo-controlled-trial/", "snippet": "<p> BACKGROUND </p><p>Preclinical models suggest alternating activation and inhibition of mechanistic target of rapamycin complex 1 (mTORC1) could enhance adaptation to exercise ('cycling hypothesis'). Whether this concept translates to older adults is unknown. This exploratory trial assessed whether once-weekly sirolimus (rapamycin) 6 mg..."}, {"title": "Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 ...", "url": "https://www.s4me.info/threads/exercise-and-weekly-sirolimus-rapamycin-in-older-adults-rapa-ex-01-randomised-double-blind-placebo-controlled-trial-2026-brad-stanfield-et-al.49847/", "snippet": "Abstract Background Preclinical models suggest alternating activation and inhibition of mechanistic target of rapamycin comp
【tool:web_search】
{"ok": true, "query": "\"RAPA-EX-01\" rapamycin older adults PMID primary endpoint", "results": [{"title": "Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 ...", "url": "https://onlinelibrary.wiley.com/doi/10.1002/jcsm.70274", "snippet": "Early human studies show that intermittent sirolimus ( rapamycin ) dosing is feasible and well tolerated in older adults . Small trials of daily dosing in coronary artery disease and aged volunteers reported minimal adverse effects but were underpowered for strength outcomes [30, 31]."}